KalVista Pharmaceuticals (NASDAQ:KALV) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report released on Thursday,Benzinga reports.

A number of other brokerages have also recently issued reports on KALV. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Stifel Nicolaus increased their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Citizens Jmp dropped their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Finally, HC Wainwright raised their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $26.66 on Thursday. The stock’s 50-day simple moving average is $18.45 and its 200 day simple moving average is $15.72. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.75 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a 52-week low of $9.83 and a 52-week high of $26.76.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the firm’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $18.28, for a total value of $730,944.08. Following the sale, the insider owned 5,089,354 shares of the company’s stock, valued at $93,033,391.12. This trade represents a 0.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul K. Audhya sold 2,686 shares of the firm’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the sale, the insider directly owned 142,547 shares in the company, valued at approximately $2,882,300.34. The trade was a 1.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 263,969 shares of company stock worth $4,536,178. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently modified their holdings of KALV. BNP Paribas Financial Markets increased its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $57,000. KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $63,000. Finally, Truvestments Capital LLC increased its position in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the last quarter.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for about $1.9 billion and to buy shares for $27.00 in cash — the deal highlights Chiesi’s push into rare-disease/HAE treatment Ekterly and is the primary catalyst for the stock’s jump. Chiesi to buy KalVista in $1.9B deal
• Positive Sentiment: Market reaction: shares surged roughly 38–39% on the takeover news and trading volume spiked well above average, reflecting investor demand to capture the cash takeover consideration. KalVista stock surges 39%
• Neutral Sentiment: Trading mechanics: trading in KALV was temporarily halted prior to the announcement for “news pending,” a routine step that precedes major corporate news and can amplify post-release moves. (Company/regulatory filings reflected the halt.)
• Neutral Sentiment: Analyst view: Needham & Company reaffirmed a “hold” rating on KalVista — a reminder some analysts view the takeover price as fair or limited upside beyond the offer. Needham reaffirms hold
• Negative Sentiment: Litigation risk: multiple shareholder-alerts and law-firm investigations (Ademi LLP and Monteverde & Associates) have been announced questioning whether the $27.00 per-share deal is fair and whether fiduciary duties were met — these actions could delay closing, prompt a negotiated price change, or produce settlement costs. Ademi LLP shareholder alert Monteverde investigation

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.